Schall, Brown & Schwartz LLP is reminding investors about a securities class action against Aardvark Therapeutics, Inc. (NASDAQ: AARD) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The complaint alleges Aardvark made false or misleading statements about the safety profile, clinical prospects and commercial prospects of its ARD-101 drug candidate during the company’s February 13, 2025, initial public offering and from February 13, 2025, through May 14, 2026. Investors who purchased shares during the relevant period and suffered losses are encouraged to contact the firm by October 13, 2026, regarding possible lead-plaintiff appointments. Lead-plaintiff status is not required to participate in any recovery, and the class has not yet been certified.